NanoViricides: Antiviral Against Influenza A Viruses Could Be Weapon to Fight Bird Flu

 NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses.

NanoViricides has recently found that its host-mimetic clinical drug candidate NV-387 was substantially superior to the three approved drugs against influenza, namely Oseltamivir (Tamiflu®, Roche), Peramivir (Rapivab®, Biocryst), and Baloxavir (Xofluza®, Shionogi, Roche) in a lethal animal model study of Influenza A/H3N2 virus lung infection.

Further, in this study, NV-387 was also found to protect the lungs of the infected animals from viral damage as well as immune system damage, supporting a strong antiviral effect.

https://www.biospace.com/article/releases/a-novel-broad-spectrum-antiviral-against-influenza-a-viruses-nv-387-could-be-an-important-weapon-to-fight-bird-flu-h5n1-says-nanoviricides/